CYAN Cyanotech Corporation
Cyanotech Corp. engages in the development and commercialization of natural products derived from microalgae. Its products include BioAstin natural astaxanthin, a dietary antioxidant shown to support and maintain the body's natural inflammatory response, to enhance skin, and to support eye and joint health; and Spirulina Pacifica, a dietary supplement used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. The company was founded by Gerald R. Cysewski in 1983 and is headquartered in Kailua-Kona, HI.
Company profile
Ticker
CYAN
Exchange
Website
CEO
Gerald R. Cysewski
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
SEC CIK
Corporate docs
IRS number
911206026
CYAN stock data
()
Investment data
Securities sold
Number of investors
Calendar
23 Jun 20
7 Aug 20
31 Mar 21
News
Company financial data Financial data
| Quarter (USD) | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|
| Revenue | 8.63M | 7.5M | 7.69M | 8.07M | |
| Net income | 121K | 171K | 228K | -133K | |
| Diluted EPS | 0.02 | 0.03 | 0.04 | -0.02 | |
| Net profit margin | 1.40% | 2.28% | 2.96% | -1.65% | |
| Operating income | 228K | 367K | 409K | 49K | |
| Net change in cash | 808K | 515K | 39K | 215K | |
| Cash on hand | 2.42M | 1.61M | 1.09M | 1.06M | |
| Cost of revenue | 5.55M | 4.63M | 4.63M | 4.4M |
| Annual (USD) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|
| Revenue | 31.9M | 30.2M | 34.12M | 32.04M | |
| Net income | 387K | -3.6M | 1.03M | -1.22M | |
| Diluted EPS | 0.06 | -0.62 | 0.18 | -0.21 | |
| Net profit margin | 1.21% | -11.91% | 3.00% | -3.79% | |
| Operating income | 1.05M | -3M | 1.41M | -682K | |
| Net change in cash | 1.58M | -489K | -78K | 167K | |
| Cash on hand | 2.42M | 840K | 1.33M | 1.41M | |
| Cost of revenue | 19.2M | 19.74M | 20.74M | 19.82M |
Financial data from Cyanotech earnings reports
Recent insider trades
| Date | Owner | Security | Transaction | Code | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|
| 30 Jul 20 | Cysewski Gerald R | RSU Common Stock | Grant | Aquire A | No | 0 | 1,999 | 0 | 2,835 |
| 30 Jul 20 | Jensen Glenn | RSU Common Stock | Grant | Aquire A | No | 0 | 1,694 | 0 | 2,295 |
| 30 Jul 20 | Johansen Jennifer M. | RSU Common Stock | Grant | Aquire A | No | 0 | 1,494 | 0 | 2,029 |
| 30 Jul 20 | Orlopp Brian Brett | RSU Common Stock | Grant | Aquire A | No | 0 | 1,686 | 0 | 1,786 |
| 30 Jul 20 | Custer Matthew Keith | RSU Common Stock | Grant | Aquire A | No | 0 | 1,588 | 0 | 1,942 |
Institutional ownership Q1 2020
11.9% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 14 |
| Opened positions | 1 |
| Closed positions | 2 |
| Increased positions | 3 |
| Reduced positions | 3 |
13F shares |
Current |
|---|---|
| Total value | 1.46M |
| Total shares | 718.48K |
| Total puts | 0 |
| Total calls | 0 |
| Total put/call ratio | – |
Largest owners |
Shares | Value |
|---|---|---|
| WFC Wells Fargo & Company | 375.18K | $754K |
| Renaissance Technologies | 148.1K | $305K |
| Coastline Trust | 82.4K | $170K |
| FineMark National Bank & Trust | 57.4K | $118K |
| California Public Employees Retirement System | 19.3K | $39K |
| MS Morgan Stanley | 14.84K | $31K |
| BLK BlackRock | 11.57K | $24K |
| Tower Research Capital | 2.89K | $6K |
| RY Royal Bank of Canada | 2.65K | $5K |
| NTRS Northern Trust | 2.36K | $5K |
Financial report summary
?Competition
CardaxManagement Discussion
- Net Sales The net sales increased $1.7 million, or 5.6%, in the year ended March 31, 2020 compared with fiscal year 2019. This increase was primarily driven by a $2.2 million, or 68.0%, increase in both astaxanthin and spirulina bulk sales and an increase in contract extraction sales of $0.3 million, offset by $0.8 million, or 3.2%, decrease in packaged sales when compared with fiscal year 2019. The bulk sales increase was primarily the result of lack of product available for our bulk customers in the prior year. The decrease in packaged sales for astaxanthin was the result of non-recurring replenishment orders in fiscal year 2019, that were the result of depleted inventory related to the re-inoculation of our ponds. Contract extraction revenue more than doubled in the current year as we continue to grow this service to third-party producers of astaxanthin biomass.
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Avg
|
|
New words:
Aid, al, annum, attend, attestation, bore, care, carryback, chain, charitable, cyber, declaratory, depleted, discount, distancing, doubled, export, farm, farming, fear, fiduciary, forgiven, freshwater, impossible, incremental, injunctive, job, magnitude, Merieux, outbreak, overseeing, pandemic, Paycheck, payroll, physical, physically, PPP, relief, shutdown, slight, slowdown, social, spread, suspend, travel, unamortized, unknown, visitor, warehousing, workforce
Removed:
amounted, Carpal, certifying, checkmark, combined, conditionally, Controller, cyberattack, detailed, DOFAW, employment, ESRC, extension, force, heart, impose, indefinite, mitigation, offsite, oral, plant, predator, reach, requested, separation, settled, sunscreen, Syndrome, targeted, topical, treatment, Tunnel, ultimate
Financial reports
10-K
2020 FY
Annual report
23 Jun 20
10-Q
2020 Q3
Quarterly report
11 Feb 20
10-Q
2020 Q2
Quarterly report
12 Nov 19
10-Q
2020 Q1
Quarterly report
13 Aug 19
10-K
2019 FY
Annual report
1 Jul 19
10-Q
2019 Q3
Quarterly report
13 Feb 19
10-Q
2019 Q2
Quarterly report
13 Nov 18
10-Q
2019 Q1
Quarterly report
13 Aug 18
10-K/A
2018 FY
Annual report (amended)
21 Jun 18
10-K
2018 FY
Annual report
15 Jun 18
Current reports
8-K
Entry into a Material Definitive Agreement
11 May 20
8-K
Submission of Matters to a Vote of Security Holders
27 Aug 19
8-K
Entry into a Material Definitive Agreement
7 Jun 19
8-K
Departure of Directors or Certain Officers
26 Apr 19
8-K
Entry into a Material Definitive Agreement
12 Apr 19
8-K
Cyanotech Names Brian Orlopp as VP Finance & Chief Financial Officer
9 Jan 19
8-K
Entry into a Material Definitive Agreement
7 Dec 18
8-K
Departure of Directors or Certain Officers
6 Nov 18
8-K
Other Events
7 Sep 18
8-K
Submission of Matters to a Vote of Security Holders
29 Aug 18
Registration and prospectus
S-8
Registration of securities for employees
10 Nov 16
D
$378.98K in equity, sold $378.98K, 1 investor
10 May 16
S-8
Registration of securities for employees
17 Sep 14
S-8
Registration of securities for employees
21 Feb 12
S-8
Registration of securities for employees
10 Oct 08
S-8
Registration of securities for employees
5 Apr 07
S-8
Registration of securities for employees
5 Apr 07
S-3
Shelf registration
22 Nov 02
REGDEX
Notice of sale of securities
25 Oct 02
S-3/A
Shelf registration (amended)
10 Aug 00
Proxies
DEF 14A
Definitive proxy
15 Jul 20
DEF 14A
Definitive proxy
10 Jul 19
DEF 14A
Definitive proxy
9 Jul 18
DEF 14A
Definitive proxy
7 Jul 17
DEF 14A
Definitive proxy
4 Nov 16
DEF 14A
Definitive proxy
15 Jul 16
DEF 14A
Definitive proxy
2 Sep 15
DEF 14A
Definitive proxy
18 Jul 14
DEF 14A
Definitive proxy
19 Jul 13
DEF 14A
Definitive proxy
18 Jul 12
Ownership
4
CYANOTECH / Amy Beth Nordin ownership change
3 Aug 20
4
CYANOTECH / Matthew Keith Custer ownership change
3 Aug 20
4
CYANOTECH / BRIAN BRETT ORLOPP ownership change
3 Aug 20
4
CYANOTECH / Jennifer M. Johansen ownership change
3 Aug 20
4
CYANOTECH / Glenn Jensen ownership change
3 Aug 20
4
CYANOTECH / Gerald R Cysewski ownership change
3 Aug 20
4
CYANOTECH / Amy Beth Nordin ownership change
15 Jul 20
4
CYANOTECH / Matthew Keith Custer ownership change
15 Jul 20
4
CYANOTECH / Jennifer M. Johansen ownership change
15 Jul 20
4
CYANOTECH / Glenn Jensen ownership change
15 Jul 20